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Abstract
Introduction: The availability of potent antiretroviral therapy has transformed HIV infection into a chronic disease such that
people living with HIV (PLWH) have a near normal life expectancy. However, there are continuing challenges in managing HIV
infection, particularly in older patients, who often experience age-related comorbidities resulting in complex polypharmacy and
an increased risk for drug-drug interactions. Furthermore, age-related physiological changes may affect the pharmacokinetics
and pharmacodynamics of both antiretrovirals and comedications thereby predisposing elderly to adverse drug reactions. This
review provides an overview of the therapeutic challenges when treating elderly PLWH (i.e. >65 years). Particular emphasis is
placed on drug-drug interactions and other common prescribing issues (i.e. inappropriate drug use, prescribing cascade, drug-
disease interaction) encountered in elderly PLWH.
Discussion: Prescribing issues are common in elderly PLWH due to the presence of age-related comorbidities, organ dysfunc-
tion and physiological changes leading to a higher risk for drug-drug interactions, drugs dosage errors and inappropriate drug
use.
Conclusions: The high prevalence of prescribing issues in elderly PLWH highlights the need for ongoing education on pre-
scribing principles and the optimal management of individual patients. The knowledge of adverse health outcomes associated
with polypharmacy and inappropriate prescribing should ensure that there are interventions to prevent harm including medica-
tion reconciliation, medication review and medication prioritization according to the risks/benefits for each patient.
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1 | INTRODUCTION
Effective antiretroviral treatments mean that persons living
with HIV (PLWH) have a chronic disease with a life expec-
tancy close to the general population [1–3], although there
are differences in estimates when considering parameters
such as HIV transmission risk group, lifestyle, race, gender or
CD4 cell counts at treatment initiation [4]. Older PLWH
includes patients infected at an older age as well as patients
diagnosed previously and who are ageing with HIV infection
[5]. Several modelling studies [6,7] have projected the increase
in median age of patients on antiretroviral treatment over the
next decade. Forty percent of the HIV population will be con-
stituted of PLWH aged ≥60 years of whom 28% are predicted
to have ≥3 comorbidities [6].
However, age-related comorbidities result in complex
polypharmacy and an increased risk for drug-drug interac-
tions (DDIs). Furthermore, physiological changes related to
ageing may affect pharmacokinetics and pharmacodynamics
thereby putting elderly PLWH at risk of inappropriate pre-
scribing. It should be noted that according to the World
Health Organization [8], the term elderly refers to
≥65 years old.
Ageing leads to physiological, anatomical and biological mod-
ifications that can alter drug pharmacokinetics [9,10]. These
changes include a reduced gastric acid secretion and a
delayed gastric emptying time, although the clinical relevance
remains unclear [10]. Drug distribution may be impaired by
the reduction in total body water and lean body mass with a
relative increase in body fat and an increased distribution of
lipophilic drugs. In addition, decreased serum albumin leads to
an increase in unbound drug and uptake in peripheral tissue.
The observed decrease in hepatic clearance (30% to 40%) in
older age results from the decline in both liver mass and
blood flow rather than changes in the activity of hepatic
enzymes [11]. Liver mass reduces by 10% to 15% and by
20% per age decade after the age of 65 years in women and
men respectively [10]. For many drugs, the most apparent
effect of ageing is the progressive decrease in renal clearance
explained by a lower glomerular filtration rate [10] resulting in
a reduced clearance of renally eliminated drugs. Since elderly
individuals are often excluded from clinical trials, there is a
lack of data on the effect of ageing on the pharmacokinetics
of antiretroviral drugs. Available data have shown that the
exposure of the non-nucleoside reverse transcriptase inhibitor
(NNRTI) efavirenz and the integrase inhibitor (INI) raltegravir
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was not significantly changed in PLWH >60 or 45 to 79 years,
whereas plasma concentrations of protease inhibitors (PI)
were increased [12–14]. Ageing impacted differently nucle-
oside reverse transcriptase inhibitors (NRTI)/nucleotide
reverse transcriptase inhibitors (NtRTI) as tenofovir exposure
was reduced by 8% to 13%, whereas conversely emtricitabine
was increased by 19% to 73% in PLWH ≥55 years [15].
Dolutegravir maximal concentrations were shown to be
increased by 25% in PLWH ≥60 years, however, this change
did not modify sleep or daytime functioning [16]. There is a
need for more pharmacokinetic data in elderly PLWH, espe-
cially those with comorbidities or frailty.
The pharmacodynamics can also be impacted by age-
associated physiological changes leading in a more or less
pronounced drug effect, particularly for cardiovascular or
central nervous systems drugs. The modification of the phar-
macodynamic effect is driven by changes in the affinity to
receptor sites or in their number as well as the alteration of
homeostatic processes with advanced age [17]. One important
example relates to the reduction in cholinergic receptors in
the brain which means that elderly PLWH are more likely to
experience central anticholinergic adverse reactions (i.e. cogni-
tive impairment, delirium) therefore drugs with anticholinergic
properties should be avoided [18].
Altogether, the presence of comorbidities and age-related
physiological changes predispose elderly PLWH not only to the
well-known risk of DDI with antiretroviral drugs but also to
other prescribing issues as discussed in the following sections.
2 | DISCUSSION
2.1 | Comorbidities among HIV-positive individuals
As summarized in Table 1, commonly observed comorbidities
which may contribute to the issue of polypharmacy in ageing
PLWH are hypertension, dyslipidaemia, diabetes mellitus, kid-
ney disease, cardiovascular disease, respiratory disorders,
bone disorders or cancer. Of interest, several studies have
reported a higher prevalence of comorbidities in PLWH com-
pared to age-matched uninfected individuals [5,19–27]. Fur-
thermore, multimorbidity defined by the concurrent presence
of ≥2 comorbidities has been shown to be significantly higher
in PLWH compared to uninfected controls, particularly in
those with a long history of HIV infection [5,19,25].
The earlier occurrence of age-related comorbidities in
PLWH compared to uninfected individuals may be explained
by factors such as immune senescence or chronic immune
activation [36] as well as lifestyle factors (e.g. smoking, alcohol
consumption, recreational drug use), viral coinfections (e.g.
hepatitis, sexually transmitted diseases) or toxicity of certain
antiretroviral drugs [37]. Metabolic disorders [38,39], renal
toxicity [40], or CNS side effects [39] are notably observed
with the first-generation antiretroviral drugs.
As expected, the number of comorbidities in PLWH has
been shown to increase with age: 18.4% of PLWH aged
≥75 years from the French Dat’AIDS cohort had ≥4 comor-
bidities versus 4.3% of those aged 50 to 74 years [32]. A sim-
ilar picture is observed in the Swiss HIV Cohort Study (SHCS)
as the number of age-associated comorbidities is significantly
higher in PLWH aged 65 years compared to those aged 50 to
64 years [35]. Importantly, the study of the SHCS has
demonstrated that the higher number of comorbidities with
ageing is correlated with a higher use of comedications and
consequently a higher risk to have polypharmacy [35].
Older age, obesity, smoking and duration of HIV infection
have been associated with an increased risk for multimorbidity
in PLWH [5,34,41]. Of interest, comorbidities have been shown
to co-occur in the same individual in specific patterns. Further-
more, correlations have also been reported between patterns
with, for instance a strong association between cardiovascular
and metabolic diseases [42]. Finally, comorbidities patterns
were shown to have different risk factors with older age and a
higher body mass index being risk factors for cardiovascular
and metabolic disorders. Finally, comorbidities patterns were
shown to affect differently health outcomes with, for example
cardiovascular disease being associated with poorer physical
health, higher risk of functional impairment, hospitalization and
a higher number of medical visits [43]. These findings could
help the development of targeted interventions to prevent,
treat and better manage multimorbidity in PLWH.
2.2 | Polypharmacy
Polypharmacy is commonly defined as the concurrent adminis-
tration of ≥5 medications, a cut-off that has been associated
with an increased risk of adverse health outcome [44]. In HIV
medicine, the term polypharmacy most often refers to non-
HIV medications given in addition to antiretroviral drugs.
Polypharmacy has been shown to be common in PLWH aged
≥50 years, ranging from 15% up to 94% as reported by sev-
eral HIV Cohort analyses summarized in Table 2 [34,45–57].
Of interest, polypharmacy was shown to be less prevalent in
the Ugandan cohort possibly due to limited access to care
and/or medications [56]. This assumption is supported by the
observation that access to care, through medication insurance
coverage and healthcare use, was shown to be a key driver
for polypharmacy in the MACS cohort [57]. Large cohort stud-
ies comparing the prevalence of polypharmacy in PLWH and
age-matched uninfected individuals have shown higher preva-
lence in infected individuals across different age categories
[52,58]. Of interest, differences in the prevalence of polyphar-
macy between PLWH and age-matched uninfected individuals
were shown to be less pronounced in older age groups (i.e.
65 to 74 and ≥75 years) [30,52]. This finding may be
explained by the natural occurrence of age-related chronic dis-
eases regardless of HIV infection.
Medications implicated in polypharmacy belong mostly to
drug classes used in older individuals such as cardiovascular
drugs, gastro-intestinal agents, hormone replacement thera-
pies or antiplatelet/anticoagulant medications [52,59].
Polypharmacy brings several challenges. The related
increase in pill burden can have a negative effect of treatment
adherence. Although available studies have shown inconsistent
findings [60–63], this is likely explained by the fact that adher-
ence is a complex behaviour involving drug-related but also
psychological factors. Polypharmacy may increase the risk of
adverse drug reactions due to the use of medications with
overlapping side effects, which may convert asymptomatic side
effects to a reason for hospitalization. Polypharmacy has been
associated with several adverse health outcomes including
physical decline, cognitive impairment, falls, hospitalization and
mortality [64–69]. However, it should be highlighted that the
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causality between polypharmacy and the aforementioned out-
comes is difficult to ascertain as the outcomes could be a
direct consequence of the primary conditions. Finally,
polypharmacy has been associated with an increased risk of
DDIs and other prescribing issues such as inappropriate drug
use, prescribing cascade or drug-disease interactions
[46,48,49,51,53,59].
Inappropriate drugs for use in elderly PLWH are generally
defined as drugs for which the risk of an adverse event out-
weighs the clinical benefit. Therefore, the use of inappropriate
drugs can lead to adverse drug reactions with the subsequent
risk of starting a prescribing cascade. The latter occurs when
an adverse drug reaction is misinterpreted as a new disease
leading to the prescription of an unnecessary medication,
which in turn, can cause an adverse drug reaction leading to
the prescription of more drugs [70]. The risk of starting a pre-
scribing cascade is higher in elderly PLWH because they are
often polymedicated and because they are more susceptible
to adverse drug reactions due to age-related physiological
changes affecting pharmacokinetics, pharmacodynamics and
homeostatic processes. Ageing PLWH could also be more sus-
ceptible to adverse drug reactions due to long-term exposure
to antiretroviral drugs leading potentially to cumulative toxic-
ity. Finally, elderly have more comorbidities and therefore are
at higher risk for drug-disease interactions. The latter occurs
when the prescription of a medication to treat a given condi-
tion may adversely aggravate a coexisting condition.
Very few studies have assessed the extent of inappropriate
prescribing in elderly PLWH. To date, only three studies have
addressed this question using tools such as the Beers criteria
and/or the STOPP/START criteria for the detection of inap-
propriate dosing, indication, treatment duration, drugs or
treatment omission [71,72]. These studies have revealed that
inappropriate prescribing was common with 52% up to 69%
of elderly PLWH presenting at least one medication problem
[46,51,53]. Importantly, prescribing issues included more often
non-HIV medications and other prescribing issues than DDIs
with antiretroviral drugs suggesting the need for education on
geriatric medicine principles. In addition, there is a need for
more real-world studies that quantify the risk associated with
various forms of polypharmacy and DDIs to help guide treat-
ment management.
Interventions to prevent unnecessary polypharmacy and
limit inappropriate prescribing include medication reconcilia-
tion, medication review and medication prioritization. The deci-
sion to prescribe should take into account the risk/benefit of
each medication, the care goals, the remaining life expectancy
and the current level of functioning as well as the patient
preference (patient-centred approach) [73]. In this context,
the concept of deprescribing or the process of dose reduction
or stopping medications that may be causing harm or no
longer provide benefit has gained increasing attention as a
means to reduce unnecessary/inappropriate polypharmacy in
elderly individuals [74].
Table 1. Prevalence of comorbidities in ageing PLWH (when available comorbidities in age-matched uninfected individuals are pre-
sented in italic)
Country data
source Population
Mean
age,
years
Diabetes,
%
Dyslipidaemia,
%
Hypertension,
%
Renal
disease,
%
CVD
disease, %
Bone
disorder,
%
Respiratory
disorder,
%
Cancer,
%
Brazil [28] 451 PLWH 58 14.9 26.7 6.7 3.1
3 HIV centres
Brazil [29] 208 PLWH 57 22.6 62.0 16.8 9.6 52.9 10.6
Brazilian cohort 208 HIV neg 57 28.4 69.7 6.7 12.5 10.1 6.3
USA [30] 2359 PLWH 71 25.9 35.7 47.9 20.9 20.3 31.3
Medicare 2 mio HIV neg 76 24.1 46.9 59.4 19.6 21.4 26.3
Portugal [31] 401 PLWH 59 13.5 60.8 39.7 8.0 5.7 9.0 8.0
7 HIV centres
France [32] 16436 PLWH 56 9.1 58.3 21.0 4.5 10.8 6.4 12.3
Dat’AIDS cohort 572 PLWH 78 22.0 60.8 43.5 29.4 23.4 12.6 22.9
France [19] 10318 PLWH 56 9.3 23.6 21.0 9.6 9.0 14.6
11 HIV centres
Europe [33] 3797 50 to 60 8.0 79.5 79.0 7.0 7.0
EuroSIDA cohorta PLWH
1837 PLWH
≥60 17.0 84.0 84.0 23.0 15.5
Italy [34] 965 PLWH 65 to 74 27.5 70.0 60.8 17.1 16.9 6.6
GEPPO cohort 224 HIV neg 65 to 74 22.3 57.8 66.5 5.0 18.3 9.1
293 PLWH ≥75 31.2 74.6 71.8 26.0 29.2 9.8
91 HIV neg ≥75 15.4 50.0 67.0 10.0 30.8 18.9
Switzerland [35] 2233 PLWH 50 to 64 7.0 69.8
SHCS cohort 450 PLWH ≥65 16.2 78.9
CVD, cardiovascular; mio, million.
aStudy period 2014.
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Of interest, markers of disease severity like the VACS index
developed for PLWH [75] or the Charlson comorbidity index
[76] might be useful indices to consider for medication priori-
tization. Furthermore, these indices may help identify individu-
als at greatest risk of harm from polypharmacy as they reflect
physiological frailty more precisely than age alone.
2.3 | Evaluating the drug-drug interaction potential
of a drug
The potential for DDIs is mainly investigated before the mar-
keting of a drug. It is important to gain an in-depth under-
standing of the disposition of the drug from in vitro data,
studies in selected animal species (bearing in mind marked
species differences in drug handling) and then first in human
studies. Some key considerations are metabolic pathways,
transporter involvement and protein binding since this will
give a framework for understanding the potential of the drug
to be a “victim” of DDIs. Similarly, there needs to be early data
on the drug as a “perpetrator” of DDIs either by induction or
inhibition of metabolic enzymes and/or transporters - these
being the key, although not exclusive, pathways of pharmacoki-
netic interactions. The aim of DDI studies performed on a
drug in development is to gain knowledge of how this new
chemical entity affects the safety and efficacy of other drugs
and vice versa. Specific DDI studies performed in healthy vol-
unteers will be based on plausible interaction mechanisms and
key/frequently used medication in the target patient popula-
tion. Overall, an early understanding of the DDI potential of a
drug is critical to ensure safety during clinical phase II and III
studies, as well as post approval. Additional studies may be
required post-approval due to emerging science or as a result
of case reports of suspected DDIs or population pharmacoki-
netic data from large phase III real-world studies.
One important emerging area is physiologically based pharma-
cokinetic modelling (PBPK) which has been applied with significant
impact during drug development and post marketing phases and
has achieved regulatory acceptance (e.g. FDA, EMA). In brief,
PBPK models represent the body and compartments parameter-
ized based on physiology of tissues and organs. PBPK models inte-
grate this physiological description with compound-specific data to
predict the pharmacokinetics of drugs, allowing simulation of the
time course of drug concentrations in plasma and tissues. This
approach is being increasingly used to simulate and predict DDIs
[77,78]. The various approaches to evaluate the DDI potential of a
given drug are depicted in Figure 1.
The consequences of an observed or predicted DDI is
assessed and treatment recommendations follow. Information
about DDIs are presented in the relevant sections of the pro-
duct label, the purpose of which is to assist the prescriber in
the use of a specific medicine. However, a recent assessment of
the consistency of DDI information in drug labels in several
countries (USA, UK, China, Japan, Korea) showed only a moder-
ate level of agreement among the countries’ labelling [79]. The
study concluded that there is a need for international harmo-
nization of the drug labelling process and regulation to produce
standardized information that can ensure safe drug therapy
worldwide. To illustrate the point of labelling differences we
show the example of the established and other potentially sig-
nificant DDIs of the integrase inhibitor dolutegravir in the US
prescribing information, the European summary of product
characteristics and Japan prescribing information [80–82]
(Table 3). It is immediately clear that there is not only different
wording used (e.g. for cation-containing antacids) but different
recommendations (e.g. carbamazepine, phenytoin).
While product labels summarize the essential clinical phar-
macology and are vital resources, the difference in interpreta-
tion of the same DDI data make other resources essential.
One seemingly “grey” area is how physicians should use “new”
medications in patients on concomitant medications that are
not mentioned in the product label. In this context a DDI
checker such as that developed by the University of Liverpool
(www.hiv-druginteractions.org) [83] is an indispensable
resource for management of DDIs.
2.4 | Mechanisms of drug-drug interactions with
antiretroviral drugs
Antiretroviral drugs have a high potential for DDIs as these
drugs can be affected by comedications (victim of DDIs) and
can also impact comedications (perpetrator of DDIs) resulting
in either a lower or higher exposure of the HIV drug or the
comedication and consequently to reduced efficacy or toxicity.
Pharmacokinetic DDIs with antiretroviral drugs can occur at
the level of absorption, metabolism or elimination via the fol-
lowing mechanisms (Figure 2):
- Gastric pH changes: Antacids markedly decrease the absorp-
tion of atazanavir [85] and rilpivirine [86] since a low pH is
required for their solubility. There is the potential for effi-
cacy to be compromised.
- Chelation: Since integrase inhibitors exert their effect by
binding to a divalent cation in the active site of the
Table 2. Prevalence of polypharmacy (≥5 non-HIV drugs) in
PLWH aged 50 years and older
Country
Number
PLWH
Age,
years
Polypharmacy,
% Reference
Switzerland 111 ≥75 60 Livio et al. 2018 [51]
Switzerland 131 ≥65 46 Courlet et al. 2019 [45]
Italy 1258 ≥65 37 Guaraldi et al. 2018
[34]
USA 1311 ≥65 43 Justice et al. 2018 [49]
USA 89 ≥60 74 Greene et al. 2014 [46]
USA 1715 ≥50 36 Ware et al. 2019 [57]
UK/
Ireland
698 ≥50 30 Halloran et al. 2019
[47]
Spain 10073 ≥50 47 Lopez-Centeno et al.
2019 [52]
Spain 242 ≥50 48 Nunez-Nunez et al.
2018 [54]
USA 248 ≥50 94 Mc Nicholl et al. 2017
[53]
USA 1312 ≥50 54 Holtzman et al. 2013
[48]
Canada 386 ≥50 43 Krentz et al. 2016 [50]
Japan 526 ≥50 35 Ruzicka et al. 2018 [55]
Uganda 411 ≥50 15 Ssonko et al. 2018 [56]
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integrase enzyme, the divalent cations aluminium, calcium
and magnesium in antacids/supplements, and also iron prod-
ucts are able to form a complex with INIs, thereby impairing
their absorption and efficacy [87–89].
- Inhibition/induction of intestinal cytochrome P450 3A4
(CYP3A4) and/or intestinal transporters: Rifampicin is a potent
enzyme/transporter inducing agent and can affect the oral
availability of TAF by increasing P-gp mediated efflux in the
enterocytes. On the other hand, PIs boosted with cobicistat
increase the absorption of dabigatran due to the inhibition of
intestinal P-gp. This increases the systemic concentrations of
dabigatran and consequently increases the risk of bleeding [90].
- Inhibition/induction of hepatic CYPs and/or glucuronidation
enzymes and/or hepatic transporters: The liver is the major
Figure 1. Evaluating the drug-drug interaction potential of a drug.
PBPK, physiologically based pharmacokinetic modelling.
Table 3. Drug-drug interactions labelling differences for dolutegravir [80–82]
Comedication US prescribing information
European summary of product
characteristics Japan prescribing information
Dofelitide Contraindicated Contraindicated Pilsicainide - Cautiona
Carbamazepine Same recommendation: DTG 50 mg twice daily in INI na€ıve patients
Oxcarbazepine Should be avoided DTG 50 mg twice daily in INI
na€ıve patients
–a
Phenobarbital Should be avoided DTG 50 mg twice daily in INI
na€ıve patients
Cautiona
Phenytoin Should be avoided DTG 50 mg twice daily in INI
na€ıve patients
Cautiona
St John’s Wort Should be avoided DTG 50 mg twice daily in INI
na€ıve patients
Cautiona
Rifampicin Same recommendation: DTG 50 mg twice daily in INI na€ıve patients
Efavirenz Same recommendation: DTG 50 mg twice daily in INI na€ıve patients
Etravirine Should not be used without ATV/r, DRV/r, or LPV/r Use 50 mg twice daily without a
bPI. Should not be used without
bPI in INI-resistant patients
Use 50 mg twice daily without a
bPI. Do not use without either
ATV/r, DRV/r, or LPV/r in
INI-resistant patients
Fosamprenavir DTG 50 mg twice daily in INI na€ıve patients No dose adjustment in INI na€ıve
patients or in absence of INI
resistance
Do not use in INI-resistant patients
Cation-containing
antacids
DTG two hours before or six hours after Antacid two hours after or six
hours before
DTG two hours before or six hours
after
Iron/calcium
supplements
DTG two hours before or six hours after Antacid two hours after or six
hours before
DTG two hours before or six hours
after but with food at the
same timea
Metformin Close monitoring; limit total daily dose Dose adjustment should be
considered
Administer with care; reduce dose
as necessarya
ATV/r, atazanavir boosted with ritonavir; bPI, boosted protease inhibitor; DRV/r,darunavir boosted with ritonavir; DTG, dolutegravir; INI, integrase
inhibitor; LPV/r, lopinavir boosted with ritonavir.
aJapan label differs from the US prescribing information and the European summary of product characteristics.
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site for DDIs and there are multiple examples of clinically
relevant DDIs. An important example is the impact of PIs
boosted with ritonavir or cobicistat on the exposure of sev-
eral statins via inhibition of CYP3A4 and/or hepatic trans-
porters thereby increasing the risk of myopathy or
rhabdomyolysis [91]. The flip side is induction and there are
many clinically relevant inducers of CYP enzymes, glu-
curonyl transferases and influx (e.g. OATP1B1/3) and efflux
(e.g. P-gp; MRP2) drug transporters.
- Inhibition of renal tubular transporters: There are some
endogenous compounds (e.g. creatinine) and several thera-
peutic agents (e.g. metformin) which are actively trans-
ported in the renal proximal tubule. Dolutegravir and
bictegravir inhibit the OCT2 mediated uptake of metformin
in the tubular cells, whereas cobicistat and ritonavir inhibit
metformin secretion in the urine via the multidrug and toxin
extrusion protein MATE1; both mechanisms increase the
exposure of the antidiabetic drug [92,93].
Pharmacodynamic DDIs may be encountered with certain
antiretroviral drugs when coadministered with drugs charac-
terized by a similar toxicity profile thereby increasing the risk
of additive adverse drug effects. As an example, both acute
and chronic renal toxicity have been associated with TDF
[40,94]. Thus, coadministration of TDF and nephrotoxic medi-
cations can increase the risk of nephrotoxicity, particularly in
PLWH with pre-existing renal impairment or when treatment
are administered for a long duration [95]. Another example is
synergistic QT prolongation when a patient is taking more
than one drug with a QT liability. The NNRTI rilpivirine has
been associated with prolongation of the QTc interval at
supratherapeutic doses and there are other drugs (e.g. esci-
talopram) which carry warnings of dose-dependent QT effects.
When possible, antiretroviral drugs with a lower potential
for DDIs such as the unboosted INIs (raltegravir, dolutegravir,
bictegravir), or the NNRTIs doravirine or rilpvirine should be
favoured where there is polypharmacy. Figure 3 shows the
DDI profile of antiretroviral drugs based on an evaluation of
DDI data with ≥750 comedications taken from the website
www.hiv-druginteractions.org [83].
Selected clinically important DDIs and their management
are presented in Table 4. More information on DDIs can be
found in the Liverpool HIV drug interactions website [83].
2.5 | Current issues when managing drug-drug
interactions
One current issue is that only few drug associations are evalu-
ated in clinical studies, thus guidance on how to manage DDIs is
mostly theoretical or is lacking, particularly when associating
mutually interacting drugs as often encountered in clinical prac-
tice. A good knowledge of the metabolic pathway of drugs and a
good understanding of the mechanisms of DDIs as well as the
therapeutic index are essential to predict the risk of having a
clinically relevant interaction. A strong inhibition or induction of
a major metabolic pathway is generally expected to cause a
large magnitude DDI that may require dosage adjustment. Con-
versely, the magnitude of DDIs will be mitigated when drugs
have multiple metabolic or elimination pathways as metabolism
and elimination can still occur through the unaffected pathways
Figure 2. Mechanisms of drug-drug interactions with antiretroviral drugs.
Victim means that the exposure of the antiretroviral drug can be increased or decreased by a comedication with inhibitory or inducing properties
on drug-metabolizing enzymes or drug transporters. Conversely, perpetrator means that the antiretroviral drug inhibits and/or induces drug-me-
tabolizing enzymes and/or transporters and therefore can alter the exposure of the coadministered drug. Figure reproduced from reference [84]
with permission from the journal Taylor & Francis (https://tandfonline.com). c, cobicistat; PI, protease inhibitor; r, ritonavir; TAF, tenofovir alafe-
namide; TDF, tenofovir disoproxil fumarate.
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[84]. A misunderstanding of these concepts and of the different
DDI of each antiretroviral drugs can lead to an overestimation
of the risk of DDI leading consequently to sub-optimal treat-
ment. This issue has been reported for antidepressants since a
larger proportion of PLWH were shown to have sub-therapeutic
antidepressants levels compared to uninfected individuals sug-
gestive of a deliberate lower dosing as clinicians fear DDIs with
antiretroviral drugs [118]. It should be highlighted that most
antidepressants are metabolized by several cytochromes and
therefore the magnitude of DDIs with boosted regimens tend
to be mitigated. In addition, the pharmacokinetic boosters riton-
avir and cobicistat inhibit only weakly cytochrome 2D6 [103],
which is the major contributor of the metabolism of most
antidepressants. Underestimating the risk of DDIs can also
occur; this is notably exemplified with the DDI between boosted
antiretroviral drugs and corticosteroids. The coadministration of
boosted antiretroviral drugs and potent corticosteroids is con-
traindicated due to the risk of developing a Cushing syndrome.
Nevertheless, these drugs are being used together in clinical
practice as indicated by two large independent European cohort
studies [52,119]. The fact that corticosteroids are administered
by different routes (oral, inhalation, intra-articular, topical) may
lead to an underestimation of the risk of DDI. In addition, corti-
costeroids are used across a large variety of medical specialties
(dermatology, pneumology or rheumatology) and therefore are
likely to be prescribed by non-HIV specialists who are not
aware of DDIs with antiretroviral drugs.
2.6 | Drug-drug interactions and long-acting
antiretroviral drugs
Long-acting drugs and formulations are an established part of
the management of several medical conditions including con-
traception, schizophrenia and osteoporosis. Long-acting drug
delivery is considered to be a key solution to the problem of
poor adherence and since daily oral pills remain a barrier to
long-term suppression of viral replication in PLWH there is
understandably much interest in both injectables and implants
of antiretrovirals [120,121]. Long-acting nanocrystal suspen-
sions of the INI cabotegravir and the NNRTI rilpivirine are in
advanced clinical development with data from large Phase III
studies in maintenance therapy (ATLAS, FLAIR) recently pre-
sented at IAS 2019 [122]. There are other exciting develop-
ments using implant technology with non-degradable
subcutaneous implants of two NRTIs - tenofovir alafenamide
(TAF) and 4ʹ-ethynyl-2-fluoro-2ʹ-deoxyadenosine (EFdA;
MK8591) - about to enter clinical testing.
Given that with non-oral drug administration, the first pass
metabolism is bypassed (i.e. the initial metabolism/disposition
within the gastrointestinal tract and liver), should it be antici-
pated that long-acting regimens will be substantially devoid of
DDIs? Clearly, DDIs are drug specific and all aspects involved
in the disposition of a given compound have to be considered.
In addition, DDIs data from other therapeutic areas have to
be reviewed. Considering contraception, the levonorgestrel
(LNG) subdermal implants are a highly efficacious and safe
form of long-acting reversible contraception. However, >50%
lower LNG exposure was shown in women receiving the LNG
subdermal implant with efavirenz-based antiretroviral treat-
ment compared to antiretroviral treatment-na€ıve women in
Uganda [123]. Despite doubling the dose of the LNG implants,
LNG concentrations remained >30% lower when women were
on efavirenz-based antiretroviral treatment [124]. Therefore,
there is uncertain contraceptive effectiveness even when
modifying the dose to overcome the DDI.
Going forward with long-acting antiretrovirals, it is almost
certain that it will be data from short-term oral DDIs studies
that will help inform PBPK modelling. For example rifampicin
administration was shown to reduce the exposure of single
oral dose cabotegravir by 59% [125]. Rajoli et al [77] then
designed PBPK models (verified against the observed data for
oral cabotegravir, rilpivirine and rifampicin) to predict the DDI
     No DDI         DDI of weak clinical relevance         DDI of clinical relevance       Deleterious DDI 
Figure 3. Drug-drug interaction profiles of selected antiretroviral drugs.
Percentage of green, yellow, amber and red DDIs considering 750 comedications listed in the Liverpool HIV interaction website [83] for selected
antiretroviral drugs belonging to the protease inhibitor (PI), integrase inhibitor (INI) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
classes. BIC, bictegravir; DRV/c, darunavir boosted with ritonavir; DRV/r, darunavir boosted with ritonavir; DOR, doravirine; DTG, dolutegravir;
EVG/c, elvitegravir boosted with cobicistat; EFV, efavirenz; ETV, etravirine; RAL, raltegravir; RPV, rilpivirine.
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Table 4. Selected clinically important drug-drug interactions and their management
Drug class ARV Comments/recommendations
Statinsa Boosted PI
Elvitegravir/c
Boosted ARVs increase the exposure of several statins. The magnitude of the DDI depends on the metabolic
pathway of the statin and its affinity to hepatic drug transporters [91]
• Simvastatin, lovastatin: contraindicated due to large magnitude DDI and related risk of rhabdomyolysis
• Other statins: start with low dose and titrate to effect. ATV is a strong inhibitor of the hepatic uptake trans-
porter OATP1B1 resulting in large magnitude DDIs with statins. Do not exceed 10 mg/day of atorvastatin
and rosuvastatin when coadministered with ATV
Calcium channel
inhibitorsa
Boosted PI
Elvitegravir/c
Boosted ARVs increase the exposure of calcium channel inhibitors due to inhibition of CYPs and thereby the
hypotensive effect
• Start at a lower dose and titrate based on blood pressure response. Consider a 50% dose reduction for
amlodipine and diltiazem [96,97]
• Lercanidipine: contraindicated
Antidiabeticsa Boosted PI
Bictegravir
Elvitegravir/c
Dolutegravir
• Sulfonylureas: boosted ARVs can potentially increase sulfonylureas concentrations due to inhibition of CYPs,
monitor glycaemic control and adjust dose as necessary.
• Metformin: DTG >BIC increase metformin exposure due to inhibition of renal transporter OCT2. Consider
adjusting metformin dose when starting DTG. No need to adjust metformin dose in patients treated with
BIC and with normal renal function otherwise close monitoring is advised [92,93]
• Saxagliptin: maximal daily dose with boosted ARVs: 2.5 mg
• Dapagliflozin, empagliflozin, exenatide, linagliptin, liraglutide, sitagliptin, vildagliptin: no clinically relevant DDIs
Vitamine K
antagonistsa
Boosted PI
Elvitegravir/c
Boosted ARVs have both inhibitory/inducing effects on CYPs and therefore are expected to alter vitamin K
antagonists effect. Closely monitor INR [98–102]
• Dose adjustments may be needed when switching pharmacokinetic booster as ritonavir has inducing proper-
ties on CYPs, whereas cobicistat does not [103]
Direct-acting
anticoagulantsa
Boosted PI
Elvitegravir/c
Boosted ARVs cause clinically significant DDIs with direct-acting anticoagulants due to inhibition of CYPs and/
or transporters. Data on management of DDIs are limited [90,104–106]
• Apixaban, rivaroxaban: avoid
• Dabigatran: coadministration is possible with PI boosted with ritonavir* but is not possible with cobicistat
boosting. (*a dose adjustment of dabigatran might be needed in patients with mild or moderate renal insuffi-
ciency)
• Edoxaban: consider a dose reduction from 60 to 30 mg
Antiplateletsa Boosted PI
Elvitegravir/c
• Aspirin: no DDIs
• Clopidogrel: boosted ARVs alter antiplatelet effect. Coadministration with boosted ARVs is not possible; use
alternative antiplatelet agents or unboosted regimens [107–109]
• Prasugrel: boosted ARVs do not alter antiplatelet effect. Coadministration with boosted regimens is possible
[109]
• Ticagrelor: contraindicated as boosted ARVs may substantially increase ticagrelor concentrations and
increase the risk of bleeding
Antacids
H2-receptor
blockers
Proton pump
inhibitors
Atazanavir
Rilpivirine
Solubility of ARV decreases as pH increases [85,86]. Administration recommendations:
• Antacids: ATV: two hours before or after antacid; RPV: four hours before or two hours after antacid
• H2-receptor blockers: ATV: simultaneous administration or >10 hours after H2-blocker. The dose of H2-
blocker should not exceed the equivalent of 40 mg famotidine twice daily (treatment na€ıve patients) or the
equivalent of 20 mg famotidine twice daily (treatment experienced patients); RPV: four hours before or
twelve hours after H2-blocker
• Proton pump inhibitors: contraindicated
Antacids
Mineral
supplements
(iron, calcium,
magnesium)
Bictegravir
Dolutegravir
Elvitegravir/c
Raltegravir
Integrase inhibitors form a complex with divalent cations at the level of the gastro intestinal tract thus
reducing their absorption [87–89,110]. Administration recommendations:
• BIC: two hours before or six hours after antacids; simultaneous with mineral supplements
• DTG: two hours before or six hours after antacids or mineral supplements
• EVG/c: separate by four hours from antacids or mineral supplements
• RAL: not recommended with aluminium- and magnesium-containing antacids. Coadministration possible with
calcium carbonate-containing antacids but only with RAL twice daily. Separate by four hours from mineral
supplements, only administration of RAL twice daily possible
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of the long-acting regimen. According to the models, there
was a predicted reduction in cabotegravir exposure of 41%
and rilpivirine of 82% for the first maintenance dose with
600 mg once daily oral rifampicin. This strongly suggests that
coadministration of rifampicin with these long-acting formula-
tions will be problematic and strategies will need to be consid-
ered to overcome the DDI. However, increasing the dose is
unlikely due to volume of injection and shortening the dosing
interval will present logistical challenges. Therefore, there are
some important challenges relating to DDIs when considering
the role out of long-acting regimens.
3 | CONCLUSIONS
DDIs in HIV really came to the forefront of attention more
than 20 years ago with the PI era and the realization that
boosting of the PI often also resulted in the boosting of other
comedications. Although we have moved into the INI era and
have unboosted regimens with a greatly reduced liability to
DDIs, there still needs to be an awareness of relevant DDIs
both with INI and the earlier generation antiretroviral drugs
which are still important in certain settings. This is particularly
relevant in the older population who often have multiple
comorbidities and therefore polypharmacy. DDIs are still an
issue we have to face and manage.
Strategies to prevent prescribing errors are important
which must include education on key DDIs with each class
of antiretroviral drugs and on prescribing principles for
specific groups of patients. Medication reconciliation and
regular medication review is essential with de-prescribing if
appropriate.
As we look to the future, there are clearly exciting develop-
ments in antiretroviral therapy particularly in relation to long-
acting injectables and implants. The question then is “will DDIs
still be an issue”? Despite bypassing gastrointestinal absorp-
tion there are still hepatic DDIs to consider (and maybe inter-
actions relating to the injection or implant site) and so we
Table 4. (Continued)
Drug class ARV Comments/recommendations
Corticosteroidsa Boosted PI
Elvitegravir/c
Boosted ARVs inhibit steroids metabolism thereby increasing the risk of Cushing syndrome. Risk is not limited
to oral administration but may also occur after topical, ocular, intra-articular or intrathecal administration of
steroids [111–113]. The risk of Cushing syndrome is not eliminated by reducing the dosage of the
corticosteroid. Avoid boosted ARVs when possible or, if unavoidable, use a corticosteroid with a lower
propensity to cause Cushing syndrome with periodic control of cortisol
• Budenoside, fluticasone, triamcinolone, mometasone: contraindicated
• Beclomethasone, methylprednisolone, hydrocortisone: can be used with boosted ARVs
• Dexamethasone can reduce the exposure of boosted ARVs particularly if used at high doses and for a long
duration. Use with caution
Antituberculosis
drugs
Rifampicin,
rifabutin
Bedaquilinea
Delamanid
Ethambutol,
isoniazid,
linezolid,
pyrazinamide
PI/r
PI/c
Elvitegravir/c
Bictegravir
Dolutegravir
Raltegravir
Doravirine
Etravirine
Rilpivirine
Efavirenz
Boosted PI
Elvitegravir/c
Boosted PI
Elvitegravir/c
ARVs
• Contraindicated with rifampicin, alternative rifabutin 150 mg once daily
• Contraindicated with rifampicin, alternative rifabutin 150 mg every other day
• Contraindicated with rifampicin, alternative rifabutin 150 mg every other day
• Contraindicated with rifampicin and rifabutin
• Dolutegravir 50 mg twice daily with rifampicin, dolutegravir 50 mg once daily with rifabutin [114].
• Raltegravir 400 mg or 800 mg twice daily with rifampicin [115], raltegravir 400 mg twice daily with rifabutin
• Contraindicated with rifampicin, alternative doravirine 100 mg twice daily with rifabutin
• Contraindicated with rifampicin, alternative rifabutin 300 mg once daily (if etravirine is administered without
PI)
• Contraindicated with rifampicin and rifabutin
• Efavirenz 600 mg once daily with rifampicin [116], increase daily dose rifabutin by 50% in presence of efavir-
enz
Boosted ARVs inhibit bedaquiline metabolism resulting in increased exposure and related increased risk of QT
interval prolongation. Given bedaquiline’s prolonged half-life, coadministration with boosted ARV should not
exceed 14 days. Monitor ECG and transaminases. Coadministration with saquinavir is contraindicated
Boosted ARVs can increase delamanid exposure resulting in an increased risk of QT interval prolongation.
Monitor ECG. Coadministration with saquinavir is contraindicated
No DDIs
More information on DDIs can be obtained from the University of Liverpool HIV drug interactions website: www.hiv-druginteractions.org [83].
ARV, antiretroviral drug; ATV, atazanavir; BIC, bictegravir; c, cobicistat; CYP, cytochromes; DDI, drug-drug interaction; DTG, dolutegravir; EVG/c,
elvitegravir/cobicistat; OATP1B1, organic anion transporting polypeptide 1B1; OCT2, organic cation transporter 2; PI, protease inhibitor; PI/c, pro-
tease inhibitor boosted with cobicistat; PI/r, protease inhibitor boosted with ritonavir; RAL, raltegravir; RPV, rilpivirine.
aDrug exposure can be lowered when coadministered with the non-nucleoside reverse transcriptase inhibitors efavirenz, etravirine and nevirapine.
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need to be clear on the process of generating key data (likely
PBPK modelling) and the strategies to deal with clinically rele-
vant DDIs.
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